NASDAQ:AVRO

AVROBIO Stock Forecast, Price & News

$9.15

-0.50 (-5.18 %)

(As of 06/18/2021 02:41 PM ET)

Add

Compare

Today's Range

$9.05

▼

$9.49

50-Day Range

$7.84

▼

$11.80

52-Week Range

$7.45

▼

$22.54

Volume9,548 shs

Average Volume566,038 shs

Market Capitalization$382.16 million

P/E RatioN/A

Dividend YieldN/A

Beta1.37

30 days | 90 days | 365 days | Advanced Chart

Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

About AVROBIO

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Gene Therapy Companies Undervalued, Positioned for Upside - Nasdaq
June 17, 2021 | nasdaq.com

Form 4 AVROBIO, Inc. For: Jun 10 Filed by: Avruch Steven - StreetInsider.com
June 15, 2021 | streetinsider.com

AVROBIO (NASDAQ:AVRO) Receives New Coverage from Analysts at BTIG Research
June 14, 2021 | americanbankingnews.com

AVROBIO, Inc. (NASDAQ:AVRO) Given Consensus Recommendation of "Buy" by Analysts
June 13, 2021 | americanbankingnews.com

AVROBIO, Inc. (NASDAQ:AVRO) Receives Average Recommendation of "Buy" from Analysts
June 13, 2021 | americanbankingnews.com

AVROBIO to Present at the JMP Securities Life Sciences Conference - Yahoo Finance
June 10, 2021 | finance.yahoo.com

AVROBIO to Present at the JMP Securities Life Sciences Conference
June 10, 2021 | finance.yahoo.com

-$0.66 Earnings Per Share Expected for AVROBIO, Inc. (NASDAQ:AVRO) This Quarter
June 9, 2021 | americanbankingnews.com

How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks - Barron's
June 7, 2021 | barrons.com

Newer methods may boost gene therapy's use for more diseases - ABC News
June 2, 2021 | abcnews.go.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVRO
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.avrobio.com
Phone617-914-8420
Employees121
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.98 per share
Price / Book1.31

Profitability

EPS (Most Recent Fiscal Year)($3.31)
Net Income$-119,710,000.00
Net MarginsN/A
Return on Equity-51.61%
Return on Assets-47.97%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares41,766,000
Market Cap$382.16 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.88 out of 5 stars

Medical Sector

140th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

23rd out of 198 stocks

4.4 Analyst's Opinion

Consensus Rating
AVROBIO has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $25.60, AVROBIO has a forecasted upside of 179.5% from its current price of $9.16.
Amount of Analyst Coverage
AVROBIO has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
AVROBIO has received 160 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AVROBIO has received 136 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AVROBIO has received 54.05% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AVROBIO and other stocks. Vote “Outperform” if you believe AVRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
AVROBIO does not currently pay a dividend.
Dividend Growth
AVROBIO does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AVROBIO insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.78% of the stock of AVROBIO is held by insiders.
Percentage Held by Institutions
80.08% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for AVROBIO are expected to grow in the coming year, from ($2.66) to ($2.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AVROBIO is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AVROBIO is -2.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AVROBIO has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

Is AVROBIO a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVROBIO stock.
View analyst ratings for AVROBIO or view top-rated stocks.

What stocks does MarketBeat like better than AVROBIO?

Wall Street analysts have given AVROBIO a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AVROBIO wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for AVROBIO.

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) released its quarterly earnings results on Wednesday, May, 12th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.12.
View AVROBIO's earnings history.

How has AVROBIO's stock price been impacted by COVID-19?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 49.5% and is now trading at $9.10.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for AVRO?

10 Wall Street analysts have issued 12 month target prices for AVROBIO's shares. Their forecasts range from $10.00 to $36.00. On average, they expect AVROBIO's share price to reach $25.60 in the next year. This suggests a possible upside of 181.3% from the stock's current price.
View analysts' price targets for AVROBIO or view top-rated stocks among Wall Street analysts.

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:

Mr. Geoff MacKay, Co- Founder, Pres, CEO & Director (Age 55, Pay $811.23k)
Mr. Erik Ostrowski M.B.A., CFO & Treasurer (Age 48, Pay $597.08k)
Mr. Steven N. Avruch J.D., Chief Legal Officer & Sec. (Age 60, Pay $506.68k)
Mr. Jeffrey Medin Ph.D., Scientific Founder
Mr. Matthew Arnold, Head of Operations
Mr. Kim Raineri M.B.A., Chief Manufacturing & Technology Officer
Dr. Christopher Mason FMEDSCI, M.D., Ph.D., FRCS, Chief Scientific Officer (Age 63)
Ms. Monique Da Silva, Sr. VP of Corp. Communications
Ms. Georgette Verdin, Chief HR Officer
Ms. Deanna M. Petersen MBA, Chief Bus. Officer (Age 59)

Who are some of AVROBIO's key competitors?

Some companies that are related to AVROBIO include REGENXBIO (RGNX), C4 Therapeutics (CCCC), Cortexyme (CRTX), ImmunityBio (IBRX), Translate Bio (TBIO), Krystal Biotech (KRYS), AlloVir (ALVR), Valneva (VALN), Ocugen (OCGN), BioAtla (BCAB), Atara Biotherapeutics (ATRA), Forma Therapeutics (FMTX), Agenus (AGEN), Cullinan Oncology (CGEM) and Vaxcyte (PCVX).
View all of AVRO's competitors.

What other stocks do shareholders of AVROBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS).

When did AVROBIO IPO?

(AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by a variety of retail and institutional investors. Top institutional investors include JPMorgan Chase & Co. (11.81%), BlackRock Inc. (8.35%), Federated Hermes Inc. (5.46%), Emerald Mutual Fund Advisers Trust (2.27%), Emerald Advisers LLC (2.20%) and Bank of New York Mellon Corp (2.05%). Company insiders that own AVROBIO stock include Bruce Booth, Christopher Paige and Geoffrey Mackay.
View institutional ownership trends for AVROBIO.

Which major investors are selling AVROBIO stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including SV Health Investors LLC, Millennium Management LLC, Goldman Sachs Group Inc., Emerald Advisers LLC, Kennedy Capital Management Inc., Credit Suisse AG, Ameriprise Financial Inc., and Nuveen Asset Management LLC.
View insider buying and selling activity for AVROBIO or view top insider-selling stocks.

Which major investors are buying AVROBIO stock?

AVRO stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., JPMorgan Chase & Co., Point72 Asset Management L.P., BlackRock Inc., Janus Henderson Group PLC, Morgan Stanley, DekaBank Deutsche Girozentrale, and Citigroup Inc..
View insider buying and selling activity for AVROBIO or or view top insider-buying stocks.

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $9.10.

How much money does AVROBIO make?

AVROBIO has a market capitalization of $380.07 million. The company earns $-119,710,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis.

How many employees does AVROBIO have?

AVROBIO employs 121 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is www.avrobio.com.

Where are AVROBIO's headquarters?

AVROBIO is headquartered at ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139.

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected].

This page was last updated on 6/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here